Author | Minzhi, Yu | |
Author | Mason, M Benjamin | |
Author | Santhanakrishnan, Srinivasan | |
Author | Emily, E Morin | |
Author | Ekaterina, Igorevna Shishatskaya | |
Author | Steven, P Schwendeman | |
Author | Anna, Schwendeman | |
Accessioned Date | 2019-07-01T07:27:06Z | |
Available Date | 2019-07-01T07:27:06Z | |
Issued Date | 2018-05 | |
Bibliographic Citation | Minzhi, Yu. Battle of GLP-1 delivery technologies [Текст] / Yu Minzhi, M Benjamin Mason, Srinivasan Santhanakrishnan, E Morin Emily, Igorevna Shishatskaya Ekaterina, P Schwendeman Steven, Schwendeman Anna // Advanced drug delivery reviews. — 2018. — № 130. | |
ISSN | 0169409X | |
URI (for links/citations) | https://www.sciencedirect.com/science/article/pii/S0169409X18301753 | |
URI (for links/citations) | http://elib.sfu-kras.ru/handle/2311/110894 | |
Abstract | Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong to an important therapeutic class for treatment of type 2 diabetes. Six GLP-1 RAs, each utilizing a unique drug delivery strategy, are now approved by the Food and Drug Administration (FDA) and additional, novel GLP-1 RAs are still under development, making for a crowded marketplace and fierce competition among the manufacturers of these products. As rapid elimination is a major challenge for clinical application of GLP-1 RAs, various half-life extension strategies have been successfully employed including sequential modification, attachment of fatty-acid to peptide, fusion with human serum albu- min, fusion with the fragment crystallizable (Fc) region of a monoclonal antibody, sustained drug delivery sys- tems, and PEGylation. In this review, we discuss the scientific rationale of the various half-life extension strategies used for GLP-1 RA development. By analyzing and comparing different approved GLP-1 RAs and those in development, we focus on assessing how half-life extending strategies impact the pharmacokinetics, pharmacodynamics, safety, patient usability and ultimately, the commercial success of GLP-1 RA products. We also anticipate future GLP-1 RA development trends. Since similar drug delivery strategies are also applied for de- veloping other therapeutic peptides, we expect this case study of GLP-1 RAs will provide generalizable concepts for the rational design of therapeutic peptides products with extended duration of action. | |
Subject | GLP-1 receptor agonist | |
Subject | Exenatide | |
Subject | Peptide delivery | |
Subject | Half-life Pharmacokinetics | |
Subject | Fatty acid conjugate | |
Subject | Albumin fusion | |
Subject | Fc fusion | |
Title | Battle of GLP-1 delivery technologies | |
Type | Journal Article | |
Type | Journal Article Preprint | |
GRNTI | 62.99.31 | |
Update Date | 2019-07-01T07:27:06Z | |
DOI | 10.1016/j.addr.2018.07.009 | |
Institute | Институт фундаментальной биологии и биотехнологии | |
Department | Кафедра медицинской биологии | |
Journal Name | Advanced drug delivery reviews | |
Journal Quartile in Scopus | Q1 | |
Journal Quartile in Web of Science | Q1 | |